Latest News and Press Releases

BURLINGAME, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Humanigen, Inc., (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on the development of next generation CAR-T and other...

GM-CSF from the donor T cells initiates a cascade that drives lethal GvHDWithout GM-CSF signaling, there was a significant reduction in acute GvHDProvide a logical rationale to administer lenzilumab...

BURLINGAME, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Humanigen, Inc., (HGEN) (“Humanigen”) a clinical stage biopharmaceutical company focused on the development of next generation cell and gene...

Expands Humanigen’s extensive intellectual property portfolio to include prevention of Graft-versus-Host Disease (GvHD)Strengthens Humanigen’s leadership position and platform in granulocyte...

Expands Humanigen’s intellectual property portfolio to include gene-edited CAR-T cellsBuilds and further strengthens Humanigen’s leadership position in GM-CSF neutralization GM-CSF neutralization has...

BURLINGAME, Calif., June 03, 2019 (GLOBE NEWSWIRE) -- Humanigen, Inc., (HGEN) (“Humanigen”) a biopharmaceutical company focused on the development of its proprietary Humaneered® monoclonal...

SANTA MONICA, Calif. and BURLINGAME, Calif., May 31, 2019 (GLOBE NEWSWIRE) -- Kite, a Gilead Company (Nasdaq: GILD) and Humanigen, Inc., (HGEN) announced today the formation of a clinical...

Severe neurotoxicity (NT) is a negative prognostic factor for overall survival with chimeric antigen receptor T-cell (CAR-T) therapyProlonged exposure of corticosteroids for severe NT may negatively...

Study Demonstrates that Dosing with Ifabotuzumab Results in Rapid, Specific and Reproducible Targeting of the Tumor Microenvironment in Patients with Glioblastoma Multiforme (GBM) Imaging Changes...

Enhanced anti-tumor activity, improved overall survival, and improved durability of response with a reduced rate of relapse observed with GM-CSF neutralization Lenzilumab (an anti-GM-CSF monoclonal...